Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients
Carlo J Iasella, Stefanie J Hannan, Emily J Lyons, Sophia C Lieber, Antu Das, Dimiter Dimitrov, Wei Li, Melissa Saul, Iulia Popescu, Ritchie Koshy, Robin Burke, Braidon Lape, Mark J Brown, Xiaoping Chen, John C Sembrat, Kaitlyn Devonshire, Georgios D Kitsios, Ioannis Konstantinidis, Mark E Snyder, Bill B Chen, Christian A Merlo, David N Hager, Joseph E Kiss, Mark H Yazer, Alan H Wells, Alison Morris, Bryan J Mcverry, Deborah K Mcmahon, Darrell J Triulzi, John F Mcdyer
PLOS ONE, doi:10.1371/journal.pone.0309449
COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of antibodies in the administered CCP influenced clinical effectiveness. In an inpatient population within a single large health system, a total of 290 CCP patients were matched to 290 controls. While CCP increased titers of anti-SARS-CoV-2 RBD IgG titers post-CCP (p = <0.0001), no differences in 30-day survival were observed between CCP patients and controls in univariate and multivariate analyses. Survival at 30 days was numerically lower in recipients who were seronegative prior to CCP administration, compared to those with low titer and high titer anti-SARS-CoV-2 RBD IgG, respectively, but did not reach statistical significance (56% vs 82% vs 75%, p = 0.16). Patients who received 2 units of high-titer CCP had numerically better survival versus those who received fewer high-titer units, but this was not statistically significant (p = 0.08). CCP did not improve 30-day survival compared to propensity matched controls. Together these data support that CCP therapy provides limited benefit to hospitalized patients with SARS-CoV-2 infection.
Supporting information
References
Abani, Abbas, Abbas, Abbas, Abbasi et al., Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial, Lancet,
doi:10.1016/S0140-6736%2821%2900897-7Abani, Abbas, Abbas, Abbas, Abbasi et al., Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial, Lancet,
doi:10.1016/S0140-6736%2821%2900897-7Agarwal, Mukherjee, Kumar, Chatterjee, Bhatnagar et al., Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ,
doi:10.1136/bmj.m3939Alemany, Millat-Martinez, Corbacho-Monne, Malchair, Ouchi et al., Hightitre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial, Lancet Respir Med,
doi:10.1016/S2213-2600%2821%2900545-2Avendaño-Sola, ´nez, Muñez-Rubio, Ruiz-Antora ´n, Molina et al., A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia, J Clin Invest,
doi:10.1172/JCI152740Bar, Shaw, Choi, Aqui, Fesnak et al., A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia, J Clin Invest,
doi:10.1172/JCI155114Casadevall, Pirofski, The convalescent sera option for containing COVID-19, J Clin Invest,
doi:10.1172/JCI138003Denkinger, Janssen, Scha ¨kel, Gall, Leo et al., Anti-SARS-CoV-2 antibodycontaining plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial, Nat Cancer,
doi:10.1038/s43018-022-00503-wDevos, Van Thillo, Compernolle, Najdovski, Romano et al., Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma, Eur Respir J,
doi:10.1183/13993003.01724-2021Ginde, Paredes, Murray, Engen, Grandits et al., Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial, Lancet Respir Med,
doi:10.1016/S2213-2600%2822%2900215-6Hamilton, Lee, Arnold, Lilford, Hemming, Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial, Int J Infect Dis,
doi:10.1016/j.ijid.2021.06.034Hueso, Pouderoux, Pe ´re, Beaumont, Raillon et al., Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19, Blood,
doi:10.1182/blood.2020008423Iasella, Hannan, Saul, Koshy, Burke et al., Funding acquisition: John F. McDyer
Ko ¨rper, Weiss, Zickler, Wiesmann, Zacharowski et al., Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19, J Clin Invest,
doi:10.1172/JCI152264Korley, Durkalski-Mauldin, Yeatts, Schulman, Davenport et al., Early Convalescent Plasma for High-Risk Outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2103784Korley, Durkalski-Mauldin, Yeatts, Schulman, Davenport et al., Early Convalescent Plasma for High-Risk Outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2103784Levine, Fukuta, Huaman, Ou, Meisenberg et al., Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials, Clin Infect Dis,
doi:10.1093/cid/ciad088Li, Scha, Kulkarni, Liu, Martinez et al., High Potency of a Bivalent Human V H Domain in SARS-CoV-2 Animal Models In Brief High Potency of a Bivalent Human V H Domain in SARS-CoV-2 Animal Models, Cell,
doi:10.1016/j.cell.2020.09.007Li, Zhang, Hu, Tong, Zheng et al., Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial, JAMA-J Am Med Assoc,
doi:10.1001/jama.2020.10044Libster, ´rez Marc, Wappner, Coviello, Bianchi et al., Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults, N Engl J Med,
doi:10.1056/NEJMoa2033700Merin, Levee, Merlo, Spector, Coleman et al., The feasibility of multiple units of convalescent plasma in mechanically ventilated patients with COVID-19: A pilot study, Transfus Apher Sci,
doi:10.1016/j.transci.2022.103423Premkumar, Segovia-Chumbez, Jadi, Martinez, Raut et al., The receptorbinding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients, Sci Immunol,
doi:10.1126/sciimmunol.abc8413Razonable, Pawlowski, Horo, Arndt, Arndt et al., Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19, eClinicalMedicine,
doi:10.1016/j.eclinm.2021.101102Senefeld, Franchini, Mengoli, Cruciani, Zani et al., COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2022.50647Senefeld, Gorman, Johnson, Moir, Klassen et al., Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis, Mayo Clin Proc Innov Qual Outcomes,
doi:10.1016/J.MAYOCPIQO.2023.09.001Starr, Czudnochowski, Liu, Zatta, Park et al., SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape, Nat,
doi:10.1038/s41586-021-03807-6Sullivan, Gebo, Shoham, Bloch, Lau et al., Early Outpatient Treatment for Covid-19 with Convalescent Plasma, N Engl J Med,
doi:10.1056/NEJMoa2119657Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2108163{ 'indexed': { 'date-parts': [[2024, 10, 25]],
'date-time': '2024-10-25T04:23:26Z',
'timestamp': 1729830206292,
'version': '3.28.0'},
'reference-count': 29,
'publisher': 'Public Library of Science (PLoS)',
'issue': '10',
'license': [ { 'start': { 'date-parts': [[2024, 10, 24]],
'date-time': '2024-10-24T00:00:00Z',
'timestamp': 1729728000000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by/4.0/'}],
'funder': [ { 'DOI': '10.13039/100000945',
'name': 'Pittsburgh Foundation',
'doi-asserted-by': 'publisher',
'id': [{'id': '10.13039/100000945', 'id-type': 'DOI', 'asserted-by': 'publisher'}]},
{'name': 'David Scaife Foundation'}],
'content-domain': {'domain': ['www.plosone.org'], 'crossmark-restriction': False},
'abstract': '<jats:p>COVID-19 convalescent plasma (CCP) was one of the first therapies to receive '
'emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP '
'in a propensity-matched analysis, and whether the presence of antibodies in the recipient at '
'the time of treatment or the titer of antibodies in the administered CCP influenced clinical '
'effectiveness. In an inpatient population within a single large health system, a total of 290 '
'CCP patients were matched to 290 controls. While CCP increased titers of anti-SARS-CoV-2 RBD '
'IgG titers post-CCP (p = <0.0001), no differences in 30-day survival were observed between '
'CCP patients and controls in univariate and multivariate analyses. Survival at 30 days was '
'numerically lower in recipients who were seronegative prior to CCP administration, compared '
'to those with low titer and high titer anti-SARS-CoV-2 RBD IgG, respectively, but did not '
'reach statistical significance (56% vs 82% vs 75%, p = 0.16). Patients who received 2 units '
'of high-titer CCP had numerically better survival versus those who received fewer high-titer '
'units, but this was not statistically significant (p = 0.08). CCP did not improve 30-day '
'survival compared to propensity matched controls. Together these data support that CCP '
'therapy provides limited benefit to hospitalized patients with SARS-CoV-2 infection.</jats:p>',
'DOI': '10.1371/journal.pone.0309449',
'type': 'journal-article',
'created': { 'date-parts': [[2024, 10, 24]],
'date-time': '2024-10-24T17:39:46Z',
'timestamp': 1729791586000},
'page': 'e0309449',
'update-policy': 'http://dx.doi.org/10.1371/journal.pone.corrections_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral '
'immunity on survival in hospitalized patients',
'prefix': '10.1371',
'volume': '19',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2668-3570',
'authenticated-orcid': True,
'given': 'Carlo J.',
'family': 'Iasella',
'sequence': 'first',
'affiliation': []},
{'given': 'Stefanie J.', 'family': 'Hannan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Emily J.', 'family': 'Lyons', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sophia C.', 'family': 'Lieber', 'sequence': 'additional', 'affiliation': []},
{'given': 'Antu', 'family': 'Das', 'sequence': 'additional', 'affiliation': []},
{'given': 'Dimiter', 'family': 'Dimitrov', 'sequence': 'additional', 'affiliation': []},
{'given': 'Wei', 'family': 'Li', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-6712-5102',
'authenticated-orcid': True,
'given': 'Melissa',
'family': 'Saul',
'sequence': 'additional',
'affiliation': []},
{'given': 'Iulia', 'family': 'Popescu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ritchie', 'family': 'Koshy', 'sequence': 'additional', 'affiliation': []},
{'given': 'Robin', 'family': 'Burke', 'sequence': 'additional', 'affiliation': []},
{'given': 'Braidon', 'family': 'Lape', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mark J.', 'family': 'Brown', 'sequence': 'additional', 'affiliation': []},
{'given': 'Xiaoping', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []},
{'given': 'John C.', 'family': 'Sembrat', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kaitlyn', 'family': 'Devonshire', 'sequence': 'additional', 'affiliation': []},
{'given': 'Georgios D.', 'family': 'Kitsios', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-6785-1318',
'authenticated-orcid': True,
'given': 'Ioannis',
'family': 'Konstantinidis',
'sequence': 'additional',
'affiliation': []},
{'given': 'Mark E.', 'family': 'Snyder', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bill B.', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []},
{'given': 'Christian A.', 'family': 'Merlo', 'sequence': 'additional', 'affiliation': []},
{'given': 'David N.', 'family': 'Hager', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joseph E.', 'family': 'Kiss', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mark H.', 'family': 'Yazer', 'sequence': 'additional', 'affiliation': []},
{'given': 'Alan H.', 'family': 'Wells', 'sequence': 'additional', 'affiliation': []},
{'given': 'Alison', 'family': 'Morris', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bryan J.', 'family': 'McVerry', 'sequence': 'additional', 'affiliation': []},
{'given': 'Deborah K.', 'family': 'McMahon', 'sequence': 'additional', 'affiliation': []},
{'given': 'Darrell J.', 'family': 'Triulzi', 'sequence': 'additional', 'affiliation': []},
{'given': 'John F.', 'family': 'McDyer', 'sequence': 'additional', 'affiliation': []}],
'member': '340',
'published-online': {'date-parts': [[2024, 10, 24]]},
'reference': [ { 'key': 'pone.0309449.ref001',
'doi-asserted-by': 'crossref',
'first-page': '1545',
'DOI': '10.1172/JCI138003',
'article-title': 'The convalescent sera option for containing COVID-19',
'volume': '130',
'author': 'A Casadevall',
'year': '2020',
'journal-title': 'J Clin Invest'},
{ 'key': 'pone.0309449.ref002',
'unstructured': 'EUA 26382 COVID-19 Convalescent Plasma. In: US Food and Drug '
'Administration [Internet]. Aug 2020 [cited 22 Mar 2023]. Available: '
'https://www.fda.gov/media/141480/download.'},
{ 'key': 'pone.0309449.ref003',
'doi-asserted-by': 'crossref',
'first-page': '2049',
'DOI': '10.1016/S0140-6736(21)00897-7',
'article-title': 'Convalescent plasma in patients admitted to hospital with COVID-19 '
'(RECOVERY): a randomised controlled, open-label, platform trial.',
'volume': '397',
'author': 'O Abani',
'year': '2021',
'journal-title': 'Lancet'},
{ 'key': 'pone.0309449.ref004',
'first-page': '371',
'article-title': 'Convalescent plasma in the management of moderate covid-19 in adults in '
'India: Open label phase II multicentre randomised controlled trial '
'(PLACID Trial).',
'author': 'A Agarwal',
'year': '2020',
'journal-title': 'BMJ'},
{ 'key': 'pone.0309449.ref005',
'first-page': '131',
'article-title': 'A multicenter randomized open-label clinical trial for convalescent '
'plasma in patients hospitalized with COVID-19 pneumonia',
'author': 'C Avendaño-Solá',
'year': '2021',
'journal-title': 'J Clin Invest'},
{ 'key': 'pone.0309449.ref006',
'article-title': 'Effect of Convalescent Plasma Therapy on Time to Clinical Improvement '
'in Patients with Severe and Life-threatening COVID-19: A Randomized '
'Clinical Trial.',
'volume': '324',
'author': 'L Li',
'year': '2020',
'journal-title': 'JAMA—J Am Med Assoc.'},
{ 'key': 'pone.0309449.ref007',
'first-page': '384',
'article-title': 'Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older '
'Adults',
'author': 'R Libster',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'pone.0309449.ref008',
'doi-asserted-by': 'crossref',
'first-page': '1700',
'DOI': '10.1056/NEJMoa2119657',
'article-title': 'Early Outpatient Treatment for Covid-19 with Convalescent Plasma',
'volume': '386',
'author': 'DJ Sullivan',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'key': 'pone.0309449.ref009',
'doi-asserted-by': 'crossref',
'first-page': 'e2250647',
'DOI': '10.1001/jamanetworkopen.2022.50647',
'article-title': 'COVID-19 Convalescent Plasma for the Treatment of Immunocompromised '
'Patients: A Systematic Review and Meta-analysis',
'volume': '6',
'author': 'JW Senefeld',
'year': '2023',
'journal-title': 'JAMA Netw Open'},
{ 'key': 'pone.0309449.ref010',
'doi-asserted-by': 'crossref',
'first-page': '1951',
'DOI': '10.1056/NEJMoa2103784',
'article-title': 'Early Convalescent Plasma for High-Risk Outpatients with Covid-19',
'volume': '385',
'author': 'FK Korley',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'pone.0309449.ref011',
'doi-asserted-by': 'crossref',
'first-page': '278',
'DOI': '10.1016/S2213-2600(21)00545-2',
'article-title': 'High-titre methylene blue-treated convalescent plasma as an early '
'treatment for outpatients with COVID-19: a randomised, '
'placebo-controlled trial',
'volume': '10',
'author': 'A Alemany',
'year': '2022',
'journal-title': 'Lancet Respir Med'},
{ 'key': 'pone.0309449.ref012',
'article-title': 'National Center for Advancing Translational Sciences, National '
'Institutes of Health [Internet].',
'author': 'National COVID Cohort Collaborative',
'year': '2022'},
{ 'key': 'pone.0309449.ref013',
'first-page': '429',
'article-title': 'High Potency of a Bivalent Human V H Domain in SARS-CoV-2 Animal Models '
'In Brief High Potency of a Bivalent Human V H Domain in SARS-CoV-2',
'volume': '183',
'author': 'W Li',
'year': '2020',
'journal-title': 'Animal Models. Cell'},
{ 'key': 'pone.0309449.ref014',
'doi-asserted-by': 'crossref',
'first-page': '8413',
'DOI': '10.1126/sciimmunol.abc8413',
'article-title': 'The receptor-binding domain of the viral spike protein is an '
'immunodominant and highly specific target of antibodies in SARS-CoV-2 '
'patients.',
'volume': '5',
'author': 'L Premkumar',
'year': '2020',
'journal-title': 'Sci Immunol'},
{ 'key': 'pone.0309449.ref015',
'first-page': '97',
'article-title': 'SARS-CoV-2 RBD antibodies that maximize breadth and resistance to '
'escape.',
'volume': '597',
'author': 'TN Starr',
'year': '2021',
'journal-title': 'Nat 2021 5977874'},
{ 'key': 'pone.0309449.ref016',
'doi-asserted-by': 'crossref',
'first-page': '499',
'DOI': '10.1016/j.mayocpiqo.2023.09.001',
'article-title': 'Mortality Rates Among Hospitalized Patients With COVID-19 Treated With '
'Convalescent Plasma: A Systematic Review and Meta-Analysis',
'volume': '7',
'author': 'JW Senefeld',
'year': '2023',
'journal-title': 'Mayo Clin Proc Innov Qual Outcomes'},
{ 'key': 'pone.0309449.ref017',
'doi-asserted-by': 'crossref',
'first-page': '1951',
'DOI': '10.1056/NEJMoa2103784',
'article-title': 'Early Convalescent Plasma for High-Risk Outpatients with Covid-19',
'volume': '385',
'author': 'FK Korley',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'pone.0309449.ref018',
'doi-asserted-by': 'crossref',
'first-page': '2077',
'DOI': '10.1093/cid/ciad088',
'article-title': 'Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to '
'Prevent Outpatient Hospitalization: A Meta-Analysis of Individual '
'Participant Data From 5 Randomized Trials',
'volume': '76',
'author': 'AC Levine',
'year': '2023',
'journal-title': 'Clin Infect Dis'},
{ 'key': 'pone.0309449.ref019',
'doi-asserted-by': 'crossref',
'first-page': 'e81',
'DOI': '10.1056/NEJMoa2108163',
'article-title': 'REGEN-COV Antibody Combination and Outcomes in Outpatients with '
'Covid-19',
'volume': '385',
'author': 'DM Weinreich',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'pone.0309449.ref020',
'doi-asserted-by': 'crossref',
'first-page': '101102',
'DOI': '10.1016/j.eclinm.2021.101102',
'article-title': 'Casirivimab–Imdevimab treatment is associated with reduced rates of '
'hospitalization among high-risk patients with mild to moderate '
'coronavirus disease-19.',
'volume': '40',
'author': 'RR Razonable',
'year': '2021',
'journal-title': 'eClinicalMedicine.'},
{ 'key': 'pone.0309449.ref021',
'doi-asserted-by': 'crossref',
'first-page': '972',
'DOI': '10.1016/S2213-2600(22)00215-6',
'article-title': 'Tixagevimab–cilgavimab for treatment of patients hospitalised with '
'COVID-19: a randomised, double-blind, phase 3 trial',
'volume': '10',
'author': 'AA Ginde',
'year': '2022',
'journal-title': 'Lancet Respir Med'},
{ 'key': 'pone.0309449.ref022',
'doi-asserted-by': 'crossref',
'first-page': '2049',
'DOI': '10.1016/S0140-6736(21)00897-7',
'article-title': 'Convalescent plasma in patients admitted to hospital with COVID-19 '
'(RECOVERY): a randomised controlled, open-label, platform trial.',
'volume': '397',
'author': 'O Abani',
'year': '2021',
'journal-title': 'Lancet (London, England).'},
{ 'key': 'pone.0309449.ref023',
'doi-asserted-by': 'crossref',
'first-page': '114',
'DOI': '10.1016/j.ijid.2021.06.034',
'article-title': 'Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of '
'the RECOVERY randomized controlled trial',
'volume': '109',
'author': 'FW Hamilton',
'year': '2021',
'journal-title': 'Int J Infect Dis'},
{ 'key': 'pone.0309449.ref024',
'article-title': 'Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients '
'with hematologic or solid cancer and severe COVID-19: a randomized '
'clinical trial.',
'volume': '4',
'author': 'CM Denkinger',
'year': '2022',
'journal-title': 'Nat Cancer.'},
{ 'key': 'pone.0309449.ref025',
'doi-asserted-by': 'crossref',
'first-page': '2290',
'DOI': '10.1182/blood.2020008423',
'article-title': 'Convalescent plasma therapy for B-cell–depleted patients with '
'protracted COVID-19',
'volume': '136',
'author': 'T Hueso',
'year': '2020',
'journal-title': 'Blood'},
{ 'key': 'pone.0309449.ref026',
'article-title': 'A randomized controlled study of convalescent plasma for individuals '
'hospitalized with COVID-19 pneumonia',
'volume': '131',
'author': 'KJ Bar',
'year': '2021',
'journal-title': 'J Clin Invest'},
{ 'key': 'pone.0309449.ref027',
'doi-asserted-by': 'crossref',
'DOI': '10.1183/13993003.01724-2021',
'article-title': 'Early high antibody titre convalescent plasma for hospitalised COVID-19 '
'patients: DAWn-plasma',
'volume': '59',
'author': 'T Devos',
'year': '2022',
'journal-title': 'Eur Respir J'},
{ 'key': 'pone.0309449.ref028',
'doi-asserted-by': 'crossref',
'DOI': '10.1172/JCI152264',
'article-title': 'Results of the CAPSID randomized trial for high-dose convalescent '
'plasma in patients with severe COVID-19',
'volume': '131',
'author': 'S Körper',
'year': '2021',
'journal-title': 'J Clin Invest'},
{ 'key': 'pone.0309449.ref029',
'doi-asserted-by': 'crossref',
'first-page': '103423',
'DOI': '10.1016/j.transci.2022.103423',
'article-title': 'The feasibility of multiple units of convalescent plasma in '
'mechanically ventilated patients with COVID-19: A pilot study.',
'volume': '61',
'author': 'NM Merin',
'year': '2022',
'journal-title': 'Transfus Apher Sci'}],
'container-title': 'PLOS ONE',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://dx.plos.org/10.1371/journal.pone.0309449',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 10, 24]],
'date-time': '2024-10-24T17:39:57Z',
'timestamp': 1729791597000},
'score': 1,
'resource': {'primary': {'URL': 'https://dx.plos.org/10.1371/journal.pone.0309449'}},
'subtitle': [],
'editor': [{'given': 'Juan P.', 'family': 'Jaworski', 'sequence': 'first', 'affiliation': []}],
'short-title': [],
'issued': {'date-parts': [[2024, 10, 24]]},
'references-count': 29,
'journal-issue': {'issue': '10', 'published-online': {'date-parts': [[2024, 10, 24]]}},
'URL': 'http://dx.doi.org/10.1371/journal.pone.0309449',
'relation': {},
'ISSN': ['1932-6203'],
'subject': [],
'container-title-short': 'PLoS ONE',
'published': {'date-parts': [[2024, 10, 24]]}}
